The impact of SGLT-2 Inhibitors on Lipid Profiles in Heart Failure Patients: a systematic review and meta-analysis

Abstract

Abstract Background and aim: Sodium-glucose cotransporter two inhibitors could reduce cardiovascular events by modulating the lipid profile in patients with heart failure, irrespective of diabetes status. In this study, we aimed to assess the effect of SGLT-2 inhibitors on heart failure patients' lipid profiles via a meta-analysis. Method PubMed, Scopus, Web of Science, and Google Scholar databases were searched up to 2023 to retrieve relevant articles' titles, abstracts, and full text. STATA software was used to conduct the meta-analysis. Result Forest plot of fasting blood sugar levels in patients receiving SGLT2 differed significantly compared to control groups (mean difference =-0.08, 95%CI [-0.13, -0.02], p < 0.05). Analysis of lipid profile items, including total cholesterol, triglyceride, HDL, and LDL in HF patients receiving SGLT2, did not show a notable difference from the control group (p > 0.005). However, the mean difference was towards reduction for LDL, cholesterol, and triglycerides and showed an increase in HDL levels. Egger’s test for publication bias revealed some publication bias (p < 0.05). Conclusion Our topic analysis did not suggest notable lipid profile alterations. In order to come to a more firm agreement, more research on heart failure subjects is necessary because there is currently insufficient evidence.